血管生成
周细胞
肠套叠(内科疾病)
癌症研究
血管内皮生长因子
生长因子
血小板源性生长因子受体
调节器
医学
萌芽血管生成
治疗性血管生成
新生血管
成纤维细胞生长因子
内皮干细胞
血管内皮生长因子受体
细胞生物学
生物
内科学
体外
外科
受体
生物化学
基因
作者
Roberto Giannì-Barrera,Mariateresa Bartolomeo,Brigitte Vollmar,Valentin Djonov,Andrea Banfi
摘要
Therapeutic angiogenesis is an attractive strategy to treat patients suffering from ischaemic conditions and vascular endothelial growth factor-A (VEGF) is the master regulator of blood vessel growth. However, VEGF can induce either normal or aberrant angiogenesis depending on its dose localized in the microenvironment around each producing cell in vivo and on the balanced stimulation of platelet-derived growth factor-BB (PDGF-BB) signalling, responsible for pericyte recruitment. At the doses required to induce therapeutic benefit, VEGF causes new vascular growth essentially without sprouting, but rather through the alternative process of intussusception, or vascular splitting. In the present article, we briefly review the therapeutic implications of controlling VEGF dose on one hand and pericyte recruitment on the other, as well as the key features of intussusceptive angiogenesis and its regulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI